http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112816708-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 2021-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112816708-B |
| titleOfInvention | Protein index for predicting sensitivity of esophageal squamous carcinoma patient to chemotherapeutic drugs and application |
| abstract | The invention belongs to the technical field of biological medicines, and particularly relates to a protein index for predicting sensitivity of an esophageal squamous carcinoma patient to chemotherapeutic drugs and application thereof. The invention discovers that the expression of FBXO31 protein of an esophageal squamous carcinoma patient is up-regulated, so that cofilin-1 phosphorylation level is reduced, and cofilin-1 activity is increased, and further, the drug resistance of the patient to paclitaxel is caused. Therefore, the up-regulation of the expression of FBXO31 protein can indicate that the patient has drug resistance to the chemotherapeutic drug paclitaxel. Before the treatment of patients with esophageal squamous cell carcinoma, the sensitivity of the patients to chemotherapeutic drugs is judged by detecting the FBXO31 protein expression condition in the patients through RT-PCR or immunohistochemistry, a judgment index is provided for doctors in the treatment process, the selection of the esophageal squamous cell carcinoma treatment drugs is guided, the medication scheme can be adjusted in time, and the treatment duration of the patients with esophageal squamous cell carcinoma is shortened to a certain extent. |
| priorityDate | 2021-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.